SUMMARY Two patients are described with proximal muscle weakness and electromyographic evidence of a myopathic process. In both, discrete carcinomatous metastatic deposits were found in proximal muscles. The possible clinical implications are discussed.
Metastatic tumour deposits within skeletal muscle are uncommon. In a survey of necropsies in 500 cancer patients such deposits were found in only four patients. ' A detailed histological study of skeletal muscle in a routine necropsy survey found metastatic tumour nodules in 16% of 38 patients with malignant diseases.2 This was not due to direct invasion of muscle from local tumour. In a number of patients with malignant disease, skeletal muscle may show either inflammatory or degenerative changes, sometimes both. 2 Clinical weakness may be explained in a number of ways. These include the non-metastatic carcinomatous neuromyopathies as well as myasthenic states, malignant cachexia, polymyositis and myopathies produced by ectopic hormone production.
Two patients are described who presented with proximal muscle weakness. Both had electromyographic (EMG) findings which supported a myopathic process, and one had added neuropathic features. In both the diagnosis of a non-metastatic carcinomatous neuromyopathy was considered although in both there were features to suggest the presence of more widespread carcinomatous involvement. In the first patient metastatic tumour deposits from a primary bronchogenic carcinoma were found in skeletal muscle at necropsy. In the second patient metastatic deposits from a primary breast carcinoma were found in a biopsy from the triceps muscle. 
Discussion
In these two patients carcinomatosis was suspected and clinically proximal muscle weakness was present which was assumed to be caused by a non-metastatic neuromyopathy. Some possible neuropathic features were also found. The EMG studies supported a myopathic process and in the first patient there were some added neuropathic features.
Both carcinomatous infiltration of muscle by metastic deposits and muscle weakness in malignant diseases are well recognised although the clinical link does not appear to have been discussed widely. Local invasion of muscle from direct tumour spread is clearly described, but discrete metastatic deposits are far less frequent. Such deposits most commonly arise from rapidly growing anaplastic tumours.' 3 In an extensive survey of muscles examined from 110 routine necropsies, abnormalities were found in 49%. These changes were most usually inflammatory or degenerative but six of 38 patients with malignant disease showed evidence of metastatic muscle deposits.2 There was no correlation between these findings and any specific muscle weakness. Metastatic deposits in muscle have also been found in the diaphragm,4 tongue,5 and extra-ocular muscles. 6 Although muscle weakness and wasting are common in malignant disease non-metastatic neuromyopathic complications are rare. Such com-plications are said to have an incidence of 7%7 and to be most common in lung cancer. EMG evidence of a myopathic process is most often found in those patients with polymyositis. In muscle biopsies from 24 cancer patients presenting with proximal muscle weakness, no metastatic deposits were found.8 Reports of EMG changes suggesting myopathic and neuropathic disturbances in patients with carcinoma are uncommon.9-"1 However lung cancer has the highest incidence and in one series approximately half of the patients had clinical evidence of proximal muscle weakness and one third depressed tendon reflexes. ' 
